leadf
logo-loader
viewBioLargo, Inc.

BioLargo says July sales doubled its monthly average thanks to new personal disinfectant

Its subsidiary Clyra Medical recently introduced Clyraguard Personal Protection Spray, an FDA-registered disinfectant for personal protective equipment

BioLargo Inc Clyraguard spray
BioLargo said that since December 31 it has converted more than $3.1 million of debt to equity

BioLargo Inc (OTCQB:BLGO) announced Tuesday that its July company wide sales more than doubled its historical monthly average thanks to its new foray into disinfectant.

Its subsidiary Clyra Medical recently introduced Clyraguard Personal Protection Spray, an FDA-registered disinfectant for personal protective equipment (PPE), such as facemasks. Deliveries of the product began in late July and production is ramping up, the company said 

“Our team at Clyra Medical developed Clyraguard in response to the Covid-19 pandemic, and we are proud that they could develop the product, secure FDA registration, secure raw materials, source FDA compliant manufacturing, and deliver product to customers in only a matter of months,” BioLargo CEO Dennis Calvert said. “We are proud of our team and this product that we believe is vital to help front line workers, and all of us, during these turbulent times.”

READ: BioLargo says subsidiary manufactures first AEC prototype to eliminate PFAS contaminants from water

Additionally, BioLargo said that since December 31, it has converted more than $3.1 million of debt to equity and that another $414,000 will be converted over the next 45 days. The company has also reached an agreement with the holders of roughly $550,000 in debt due in August to extend the maturity date by one year and convert a portion of the principal into equity. 

“The continued balance sheet improvements are dramatic,” Calvert said. “We have been diligent to move away from convertible debt instruments in favor of equity-based transactions for new capital, and have not taken in any new convertible debt since September of 2019, so as to eliminate the extremely expensive non-cash interest expense. ... As we are emerging from the height of the Covid-19 crisis, we are glad to see capital projects being restarted which bodes well for ONM Environmental, BioLargo Engineering and BioLargo Water.”

Calvert said BioLargo was recently notified of an award of public funding to support the first commercial installation of its Advanced Oxidation System, and BioLargo Engineering is preparing for commercial trials for our PFAS solution (the BioLargo Aqueous Electrostatic Concentrator) in the coming months.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: BioLargo, Inc.

Price: 0.15158 USD

OTCMKTS:BLGO
Market: OTCQB
Market Cap: $32.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

BioLargo says study reports its CupriDyne disinfectant kills the coronavirus...

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive that its patented CupriDyne disinfectant was able to completely inactivate the SARS-CoV-2, the virus that causes COVID-19, in just 10 minutes. Calvert says the results were achieved in a third-party study of a modified CupriDyne...

3 weeks, 4 days ago

2 min read